Literature DB >> 7692640

A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells.

S C Wang1, P A Morel, Q Wang, M L Jordan, R L Simmons, D J Tweardy.   

Abstract

FK-506 is known to suppress the transcription of several genes encoding cytokines (e.g., IL-2, IFN-gamma) thought to play an important role in the allograft response. This general inhibition of cytokine gene transcription and protein production was previously thought to be the main mechanism by which FK-506 suppressed the immune response. We have studied the pattern of cytokine suppression caused by FK-506 in differentiated murine Th 2 cell lines. Supernatants from Th2 cells treated with FK-506 showed marked suppression of IL-4 but only moderate suppression of IL-10 levels. To determine whether this differential effect on IL-4 and IL-10 could also be seen at the mRNA level, total cellular RNA was isolated from cells treated with (1) media, (2) Con A (2 micrograms/ml), (3) FK-506 (50 ng/ml), or (4) Con A + FK-506. Reverse transcription-polymerase chain reaction and northern blot analysis were used to measure IL-4 and IL-10 mRNA. Similar to results at the protein level, FK-506 suppressed steady state levels of IL-4 mRNA markedly but had a lesser effect on steady state levels of IL-10 mRNA. Furthermore, FK-506 completely abrogated Con A-induced upregulation of IL-4 mRNA, but only slightly suppressed Con A-induced upregulation of IL-10 mRNA. IL-10 (cytokine synthesis inhibitory factor) is a cytokine with immunosuppressive properties that itself inhibits the production of IL-2 and IFN-gamma murine helper cells. IL-10 also downregulates MHC II expression and antigen presentation by monocytes. Therefore, the ability of FK-506 to differentially suppress the mRNA levels of immunostimulatory cytokines such as IL-2, IL-4, and IFN-gamma more than the mRNA levels of the immunosuppressive cytokine IL-10 suggests that the effective immunosuppression seen in vivo with FK-506 may be a combination of these 2 effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692640     DOI: 10.1097/00007890-199310000-00038

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Tacrolimus rescue therapy for renal transplant rejection.

Authors:  M L Jordan; R Shapiro; R Naraghi; D Smith; C Vivas; H A Gritsch; V Scantlebury; P Randhawa; A J Demetris; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1996-08       Impact factor: 1.066

2.  Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.

Authors:  P S Randhawa; A C Tsamandas; M Magnone; M Jordan; R Shapiro; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

Review 3.  Xenobiotics, chimerism and the induction of tolerance following organ transplantation.

Authors:  C P Delaney; A W Thomson; A J Demetris; T E Starzl
Journal:  Ther Immunol       Date:  1994-06

4.  Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells.

Authors:  X Zhu; M Imamura; S Hashino; J Tanaka; S Kobayashi; H R Tao; M Asaka; M Kasai; T Matsudaira; S Asano
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

5.  Tacrolimus rescue therapy for renal allograft rejection--five-year experience.

Authors:  M L Jordan; R Naraghi; R Shapiro; D Smith; C A Vivas; V P Scantlebury; H A Gritsch; J McCauley; P Randhawa; A J Demetris; J McMichael; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1997-01-27       Impact factor: 4.939

Review 6.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

7.  FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression.

Authors:  M L Jordan; R Shapiro; C A Vivas; V P Scantlebury; P Rhandhawa; G Carrieri; J McCauley; A J Demetris; A Tzakis; J J Fung
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

8.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

Review 9.  Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets.

Authors:  Quincy A Quick
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.